Brief: DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT

21/05/2024 13:30

May 21 (Reuters) - DURECT Corp  DRRX.O :
    * DURECT CORPORATION RECEIVES FDA BREAKTHROUGH THERAPY
DESIGNATION
FOR LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS
    * DURECT CORP -DURECT PLANS TO CONFIRM EFFICACY AND SAFETY
OF
LARSUCOSTEROL IN A REGISTRATIONAL PHASE 3 CLINICAL TRIAL

Source text for Eikon:  ID:nPn5hllDTa 
Further company coverage:  DRRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))